



Medicines & Healthcare products
Regulatory Agency



D Jackson
request_820353_c470a28f@whatdotheyknow.com

MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

www.gov.uk/mhra

7th February 2022

Dear D Jackson,

FOI 22/021 COVID 19 Adverse Reaction procedures, policies and templates

Thank you for your Freedom of Information request dated 6th January, where you asked for information on the following:

Please provide the following in relation to COVID 19 vaccines:

Procedures and policies relevant to the investigation of adverse reactions reported to the MHRA.

Templates used for reporting adverse reaction data and investigations of adverse reactions to stakeholders.

As with any vaccine or medicine, COVID 19 vaccines require continuous safety monitoring to ensure that the benefits in protecting people against COVID 19 outweigh any side effects or potential risks. Further information, specifically relating to the safety monitoring process for COVID 19 vaccines is outlined in the COVID 19 Vaccine Surveillance Strategy. Please follow this link to the document: <https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-expert-working-group-on-covid-19-vaccine-safety-surveillance/report-of-the-commission-on-human-medicines-expert-working-group-on-covid-19-vaccine-safety-surveillance>

Information on how the MHRA monitors the safety of all medicines and vaccines can be found via the following [link](#). As described in the link, investigation of adverse drug reaction (ADR) reports, known as signal detection, is performed using specialised software. This software analyses all drug reaction combinations on the MHRA's database to identify combinations that occur more frequently than would be expected compared to background rates. 'Signals' that meet defined criteria are then assessed by a multidisciplinary team of experts to determine the likelihood of a causal relationship between the drug and the reaction, and to determine if regulatory action is appropriate.

With regards to your second question, on how the MHRA communicates with stakeholders, this is also addressed in the second link provided above "How the MHRA monitors the safety of medicines". As the document describes, where a new harm is identified, or new information about an existing side effect comes to light, the product information will be amended accordingly. Changes



Medicines & Healthcare products
Regulatory Agency



may also be communicated via the Drug Safety Update to alert clinicians of the new information:
https://www.gov.uk/drug_safety_update.

With regards to communication specifically related to COVID 19 vaccine matters, you may already be aware that we are publishing a weekly summary of Yellow Card reporting which is available here: https://www.gov.uk/government/publications/coronavirus_covid_19_vaccine_adverse_reactions/coronavirus_vaccine_summary_of_yellow_card_reporting

I hope the information provided is helpful.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team,
Vigilance and Risk Management of Medicines Division

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re use of MHRA information, please visit
https://www.gov.uk/government/publications/reproduce_or_re_use_mhra_information/reproduce_or_re_use_mhra_information

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.